Therapeutic effect of fecal microbiota transplantation on rats with liver cirrhosis and its influence on gut microbiota

Document Type : Original Article


1 Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, Fujian, China

2 Department of Gastroenterology, Fujian Provincial Hospital South Branch, Fuzhou 350028, Fujian, China

3 Department of Gastroenterology, Fujian Provincial Hospital, Fuzhou 350001, Fujian, China



Objective(s): This study aimed to explore the therapeutic effect of fecal microbiota transplantation (FMT) on liver cirrhosis-induced rat models by studying changes in intestinal flora distribution and liver pathology. 
Materials and Methods: Cirrhosis was induced in adult male Sprague-Dawley rats using carbon tetrachloride; successful establishment of the cirrhosis model was verified using hematoxylin and eosin (HE) staining. Rats were divided into normal control, cirrhosis model+normal saline, and cirrhosis model+FMT groups. Fecal intestinal flora was analyzed using 16S rRNA high-throughput sequencing for each group. Alpha diversity, beta diversity, and functional prediction analyses were performed. Additionally, rat liver tissue was subjected to HE staining to compare the degree of fibrosis and liver damage between the groups.
Results: FMT significantly improved the diversity, richness, and uniformity of the intestinal flora in rats with liver cirrhosis. Notably, post-FMT, the abundance of lactobacillaceae, bacilli, and bacteroidia increased, while the abundance of clostridia decreased. Moreover, hepatic fibrosis improved after FMT.
Conclusion: The dysbiosis of intestinal flora in rats with liver cirrhosis improved after FMT. Thus, FMT can regulate intestinal flora, reduce liver inflammation, and improve hepatic fibrosis and cirrhosis.


Main Subjects

1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019; 70: 151-171.
2. Premkumar M, Anand AC. Overview of Complications in Cirrhosis. J Clin Exp Hepatol 2022; 12:1150-1174.
3. de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: Mechanistic insights. Gut 2022;7:1020-1032.
4. Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: Physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol 2018; 12: 641-656.
5. Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021; 75: S67-S81.
6. Hatton G, Shawcross DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis? Expert Rev Gastroenterol Hepatol 2019; 13: 1-2.
7. Seong H, Lee SK, Cheon JH, Yong DE, Koh H, Kang YK, et al. Fecal microbiota transplantation for multidrug-resistant organism: Efficacy and response prediction. J Infection 2020;81:719-725.
8. Sun Z, Westermann C, Yuan J, Riedel CU. Experimental determination and characterization of the gap promoter of Bifidobacterium bifidum S17. Bioengineered 2021; 5: 371-377.
9. Wortelboer K, Nieuwdorp M, Herrema H. ​​Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 2019; 44: 716-729.
10. Basson A, Zhou Y, Seo B, Rodriguez-Palacios A, Cominelli F. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res 2020; 226: 1-11.
11. Qu Z, Tian P, Yang B, Zhao J, Wang G, Chen W. Fecal microbiota transplantation for diseases: Therapeutic potential, methodology, risk management in clinical practice.Life Sci 2022; 304: 120719.
12. Yang J, Yang H, Li Y. The triple interactions between gut microbiota, mycobiota and host immunity. Crit Rev Food Sci Nutr 2023; 63:11604-11624.
13.Schneider KM, Albers S and Trautwein C. Role of bile acids in the gut-liver axis. J Hepatology 2018; 68: 1083-1085.
14. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: A pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012; 42:439-446.
15. Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, et al. Liver steatosis, gut-liver axis, Microbiome and environmental factors. A never-ending bidirectional cross-Talk. J Clin Med 2020; 9: 2648-2691. 
16. García-Lezana T, Raurell I, Bravo M, Torres-Arauz M, Salcedo MT, Santiago A, et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology 2018; 67: 1485-1498.
17. Wang WW, Zhang Y, Huang XB, You N, Zheng L, Li J. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction. World J Gastroenterol 2017; 23: 6983-6994.
18. Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 2015; 30: 51-58.
19. Kozich J J, Westcott S L, Baxter N T, et al. Development of a dual-index sequenci ng strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq I llumina sequencing platform. Appl Environ Microbiol 2013, 79: 5112-5120.
20. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis 2020; 21:127-138.
21. Li D, Cui L, Gao Y, Li Y, Tan X, Xu H. Fecal microbiota transplantation improves intestinal inflammation in mice with ulcerative colitis by modulating intestinal flora composition and down-regulating NF-kB signaling pathway. Microb Pathog 2022; 173:105803.
22. Xiaoxia G, Na H, Xiaoxiao L, Yuanpei S, YuZhen L, Lei L, et al. Analysis of the characteristics and driving factors of intestinal flora imbalance in patients with liver cirrhosis. J Clin Hepatobil Dis 2020; 36: 1527-1533. 
23. Dan L, Jian G. Relationship between intestinal flora imbalance and liver cirrhosis. Adv Clin Med 2022; 12: 2510-2518.
24. Jaramillo AP, Awosusi BL, Ayyub J, Dabhi KN, Gohil NV,  Tanveer N, et al. Effectiveness of fecal microbiota transplantation treatment in patients with recurrent clostridium difficile infection, ulcerative colitis, and crohn’ s disease: A systematic review. Cureus 2023,15:e42120.-42124
25. Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, et al. Impact of fecal microbiota transplantation on obesity and metabolic syndrome-a systematic review. Nutrients 2019; 11: 2291-2306.
26. Liang Q, Zhang M, Hu Y, Zhang W, Zhu P, Chen Y, et al. Gut microbiome contributes to liver fibrosis impact on T cell receptor immune repertoire. Front Microbiol 2020; 11: 571847-571860. 
27. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. Hepatol Res 2021; 51:725-749.